On April 27, CMS issued two proposed rules titled “Ensuring Access to Medicaid Services” and “Medicaid and Children’s Health Insurance Program (CHIP) Managed Care Access, Finance and Quality”.

These rules cover a broad range of proposed policies intended to improve transparency and access to care. Below, ADVI provides highlights from the proposed rules. If you have any questions or would like further information, please do not hesitate to get in touch.

Ensuring Access to Medicaid Services Proposed Rule
States are required to periodically assess whether beneficiaries have sufficient access to care using metrics such as enrolled providers in a geographic area, changes in utilization of covered services, beneficiary population characteristics, and provider payment rates. However, the evaluation process is not standardized and limits comparisons between the States.

  • CMS proposes to rescind the current requirements entirely and replace it with new requirements. Specifically, these new requirements would:
    • Require States publish approved FFS Medicaid payment rates in a clearly accessible, public location on their website no later than January 1, 2026 or approximately 2 years after the effective date of the final rule.
    • For certain services such as primary care, OB/GYN and outpatient behavioral health, conduct a comparative payment rate analysis between Medicaid and Medicare and make this analysis publicly available. This comparative analysis would be updated no less than every 2 years starting January 1, 2026.
    • Establish standard information that States must submit as part of a State Plan Amendment (SPA) that includes provider payment rate reductions or restructuring that could diminish patient access. States would be required to submit additional analyses if any of the following apply:
      • Aggregate Medicaid payment rates are below 80% of Medicare payment ratesChanges to Medicaid payment rates would result in a >4% reduction in FFS Medicaid expenditure during the fiscal year.
      • Public comment processes raise access to care concerns from patients, providers or other interested parties.
  • CMS considered, but did not propose, including covered outpatient drugs (including professional dispensing fees) as an additional category of service in the comparative payment rate analysis due to the complexity of drug pricing policies and use of rebate programs that does not fit into their proposed comparative payment rate analysis methodology.
    • CMS is still seeking public comment regarding the decision not to include inpatient behavioral health services and covered outpatient drugs including professional dispensing fees as additional proposed categories of services subject to the comparative payment rate analysis requirements in proposed § 447.203(b)(2).


Medicaid and Children’s Health Insurance Program (CHIP) Managed Care Access, Finance, and Quality Proposed Rule

  • Establishes maximum appointment wait time standard for certain services and requires states to conduct enrollee experience surveys for each managed care plan starting 3 years after the effective date of the final rule.
  • Requires managed care plans to submit to States a payment analysis comparing managed care payment rates to Medicare payment rates for primary care, OB/GYN, mental health and substance use disorder services. States would then be required to submit this information to CMS starting 2 years after the effective date of the final rule
  • Allow states to use state directed payments to implement value based payment arrangements and include non-network providers.
  • These policies would establish the MAC QRS as a one-stop-shop where beneficiaries could access information about Medicaid and CHIP eligibility and managed care; including comparing plans based on quality and other factors key to beneficiary decision making, such as the plan’s drug formulary and provider network.

ADVI will continue monitoring developments and next steps. This is a delayed release. ADVI Instant content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


Lindsay Bealor Greenleaf, JD, MBA
Senior Vice President, Market Access and Policy Strategy

CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.